143 related articles for article (PubMed ID: 8522818)
1. Revised drug policy.
Shelat AJ
J Indian Med Assoc; 1995 Mar; 93(3):117-8. PubMed ID: 8522818
[No Abstract] [Full Text] [Related]
2. New rules for US drug reimbursement.
Bouchie A
Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
[No Abstract] [Full Text] [Related]
3. Drug price deal spells windfall for researchers.
Bosch X
Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
[No Abstract] [Full Text] [Related]
4. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices.
Moken MC
Am J Law Med; 2003; 29(4):525-42. PubMed ID: 15119247
[No Abstract] [Full Text] [Related]
5. Impact of gatt agreement on drug prices.
Pillai AM
J Indian Med Assoc; 1995 Mar; 93(3):113, 120. PubMed ID: 8522810
[No Abstract] [Full Text] [Related]
6. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
Curti AM
Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
[No Abstract] [Full Text] [Related]
7. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
8. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
9. New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit?
Toop L; Richards D; Saunders B
N Z Med J; 2003 Aug; 116(1180):U556; discussion U556. PubMed ID: 14581976
[No Abstract] [Full Text] [Related]
10. Prescription drug prices in Canada.
Gross D
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
[No Abstract] [Full Text] [Related]
11. Interview with Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry.
Barker R
Future Med Chem; 2009 Jun; 1(3):421-6. PubMed ID: 21426122
[No Abstract] [Full Text] [Related]
12. Bid to limit prices on drugs using 'public' discoveries.
Wadman M
Nature; 1998 May; 393(6683):297. PubMed ID: 9620788
[No Abstract] [Full Text] [Related]
13. Bringing business risk into sharp focus.
Gruber B; Walsh E
Nat Biotechnol; 2012 Jan; 30(1):30-2. PubMed ID: 22231088
[No Abstract] [Full Text] [Related]
14. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"].
Schmidt K
MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398
[No Abstract] [Full Text] [Related]
15. A tough market.
Ridley-Smith RM
N Z Med J; 2007 Aug; 120(1260):U2699. PubMed ID: 17726506
[No Abstract] [Full Text] [Related]
16. NIH urged to cap profits made on publicly funded research.
Macilwain C
Nature; 2000 Jul; 406(6791):5. PubMed ID: 10894508
[No Abstract] [Full Text] [Related]
17. Pharmaceutical industry financial performance.
Goodman M
Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
[No Abstract] [Full Text] [Related]
18. [Pharmaceutical specialities: definitions and rules for manufacturing and marketing in Italy].
Germani C; Montanari L; Petraroja A
Boll Chim Farm; 1979 Mar; 118(3):135-43. PubMed ID: 475905
[No Abstract] [Full Text] [Related]
19. The new drug policy.
Dutta GP
J Indian Med Assoc; 1987 Nov; 85(11):321-3. PubMed ID: 3448133
[No Abstract] [Full Text] [Related]
20. WHO must defend patients' interests, not industry.
Cawthorne P; Ford N; Limpananont J; Tienudom N; Purahong W
Lancet; 2007 Mar; 369(9566):974-5. PubMed ID: 17382809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
